Actively Recruiting
Evaluating Psilocybin Safety and Tolerability as an Adjunct Treatment for Chronic Stroke Recovery Phase 1 Clinical Study
Led by Johns Hopkins University · Updated on 2026-02-13
20
Participants Needed
1
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Stroke is a leading cause of death and disability worldwide, with many survivors experiencing long-term impairments in language, cognition, motor, and sensory skills. Rehabilitation after stroke is often limited by a critical period during which recovery is most effective. Researchers are exploring whether psychedelic compounds like psilocybin can reopen this critical period, potentially enhancing recovery. This study focuses on evaluating the safety and tolerability of psilocybin in patients with chronic stroke, while also assessing its effects on motor recovery. Participants will receive one of two psilocybin treatments a single 25 mg dose or two 12.5 mg doses spaced 2 hours apart. The study is randomized and unblinded. The intervention is given under medical supervision, and the research team will closely monitor vital signs and other safety parameters during and after dosing. During the study, participants will undergo assessments including blood pressure, heart rate, oxygen saturation, EKG, and psychiatric symptoms up to 24 hours post-administration. Longer-term evaluations at 30 and 90 days will measure neurological impairment, motor function, arm-hand recovery, cognitive function, gait, and mood using various standardized tests and questionnaires. Safety monitoring includes tracking adverse events and laboratory tests. The total participation time spans from initial dosing through follow-up assessments up to 90 days.
CONDITIONS
Brief Title
Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability
Research Team
S
Steven R Zeiler, M.D., Ph.D.
V
Victor C Urrutia, M.D.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here